Wang Xin-Rui, Zhou Bi-Ting, Zheng Qing-Mei, Wang Ya-Duan, Huang Qiu-Kai, Song Xuan, Wang He, Zhang Nan-Wen, Zhu Yi-Hua, Chen Xiao-Le, Yang Ju-Hua
Department of Bioengineering and Biopharmaceutics, School of Pharmacy, Fujian Medical University, Fuzhou 350122, Fujian Province, China.
Department of Ophthalmology, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350122, Fujian Province, China.
Int J Ophthalmol. 2020 Dec 18;13(12):1976-1982. doi: 10.18240/ijo.2020.12.20. eCollection 2020.
To evaluate the feasibility of promoting genetic detection for granular corneal dystrophy type 2 (GCD) by a questionnaire conducted among citizens in five cities in China.
The data were collected by questionnaire, and analyzed by Chi-square test and one-tailed test in IBM SPSS statistics.
Based on the survey data on the awareness of GCD genetic detection in this study and the positive predictive analysis report of the citizens in five cities in China, the vast majority (84.2%) of respondents had never heard of it and did not know that GCD patients have been prohibited from performing excimer surgery that can deteriorate GCD patients' condition even leading to blindness. Though 3.4% of patients understood GCD very much, they have no idea that GCD could not be 100% accuracy diagnosed by the conventional inspection methods.
It is feasible and necessary to use GCD genetic detection as an excimer preoperative examination project. In order to promote the development of detection project, a few improvements should be carried out in terms of the promoting efforts, costs, and research progress.
通过对中国五个城市市民进行问卷调查，评估推广颗粒状角膜营养不良2型（GCD）基因检测的可行性。
通过问卷调查收集数据，并在IBM SPSS统计学软件中采用卡方检验和单尾检验进行分析。
基于本研究中关于GCD基因检测知晓情况的调查数据以及中国五个城市市民的阳性预测分析报告，绝大多数（84.2%）受访者从未听说过GCD基因检测，也不知道GCD患者已被禁止进行准分子手术，这种手术会使GCD患者病情恶化甚至导致失明。尽管3.4%的患者对GCD非常了解，但他们并不知道传统检查方法无法100%准确诊断GCD。
将GCD基因检测作为准分子术前检查项目是可行且必要的。为推动检测项目的发展，应在推广力度、成本和研究进展方面进行一些改进。
